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Background: Dementia affects over 4 million people in the US and is frequently unrecognized and underdiagnosed
in primary care. Routine dementia screening in primary care is not recommended by the US Preventive Services
Task Force due to lack of empirical data on the benefits and harms of screening. This trial seeks to fill this gap and
contribute information about the benefits, harms, and costs of routine screening for dementia in primary care.
Methods/Design: Single-blinded, parallel, randomized controlled clinical trial with 1:1 allocation. A total of 4,000
individuals aged ≥65 years without a diagnosis of dementia, cognitive impairment, or serious mental illness receiving
care at primary care practices within two cities in Indiana. Subjects will be randomized to either i) screening for
dementia using the Memory Impairment Screen Telephone version or ii) no screening for dementia. Subjects who
screen positive for dementia will be referred to the local Aging Brain Care program that delivers an evidence-based
collaborative care model for dementia and depression. Research assistants will administer the 15-item Health Utility
Index, Patient Health Questionnaire, Generalized Anxiety Disorder Scale, and Medical Outcomes Study at baseline, 1, 6,
and 12 months. Information about advanced care planning will be collected at baseline and 12 months. All enrollees’
medical records will be reviewed to collect data on health care utilization and costs.
Discussion: We have two primary hypotheses; first, in comparison to non-screened subjects, those who are screened
and referred to a dementia collaborative care program will have a higher health-related quality of life as measured by
the Health Utility Index at 12 months post-screening. Second, in comparison to non-screened subjects, those who are
screened and referred to a dementia collaborative care program will not have higher depression or anxiety at one
month post-screening as measured by the Patient Health Questionnaire and Generalized Anxiety Disorder Scale scales.
Our secondary hypothesis is that screened subjects will have an Incremental Cost-Effectiveness Ratio below the
maximum acceptable threshold of $60,000 per quality adjusted life year saved at 12 months.
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Dementia is a debilitating chronic brain syndrome that is
estimated to affect 4.5 million people in the United States
[1,2]. Currently, Medicare beneficiaries with dementia
account for 34% of Medicare spending, even though they
constitute only 13% of the beneficiaries aged 65 and older.
By 2050, Medicare spending related to dementia will sur-
pass $1 trillion [3]. Most patients with dementia are cared
for in primary care settings with the majority of these
cases being unrecognized [4,5]. Some argue that screening
for dementia in primary care is the optimal strategy to
increase dementia recognition and thus reduce dementia-
related societal cost [5,6]. However, the United States Pre-
ventive Services Task Force did not find any randomized
controlled trials of routine dementia screening and con-
cluded that the evidence to systematically screen for de-
mentia in primary care is insufficient [7,8]. Nevertheless,
the Center for Medicare and Medicaid Services is cur-
rently covering the costs of an Annual Wellness visit for
Medicare beneficiaries that includes the detection of cog-
nitive impairment [9]. Hypothesized benefits for dementia
screening include the opportunity to identify reversible
causes of impairment, initiate early pharmacological and
non-pharmacological interventions, and enhance patient
and caregiver education and planning about the disease
and its course. Hypothesized harms include inducing de-
pression and anxiety once diagnosed and labeling patients
who might suffer from stigmatization.
In order to fill the gaps in the literature regarding the
benefits and harms of dementia screening, scientists at the
Indiana University (IU) Center for Aging Research are
conducting a randomized controlled dementia screening
trial called the IU CHOICE trial. The CHOICE trial will
contribute important information to patients, families,
providers, and policy-makers about the harms and bene-
fits of routine screening for dementia in primary care. If
this trial is successful, it not only will address the appro-
priateness of routine screening for dementia, it also will
provide a template for the successful implementation of
screening programs, coupled with diagnosis and treatment
programs, that are practical for a broad range of health
care systems.
The outcomes of the CHOICE trial are the impact of
routine screening in primary care, coupled with a col-
laborative dementia care program, on patients’ health-
related quality of life, mood, and anxiety. In addition, the
CHOICE trial has a secondary outcome of the cost ef-
fectiveness of dementia screening in primary care. We
hypothesize that screened subjects, compared with non-
screened subjects, will have a higher health-related quality
of life as measured by the Health Utility Index (HUI) at
12 months post-screening; screened subjects will not have
higher depression or anxiety at one month post-screening
(as measured by the Patient Health Questionnaire (PHQ-9)and Generalized Anxiety Disorder (GAD-7) scales); and
screened subjects will have an incremental cost-effective-
ness ratio (ICER) below the maximum acceptable thresh-
old of $60,000 per quality adjusted life year (QALY) saved
at 12 months.
Methods/Design
Design
This clinical study is a pragmatic, two-center, randomized,
controlled, single-blind study of dementia screening in pri-
mary care, coupled with a collaborative dementia care pro-
gram. The study will recruit 4,000 adults aged 65 and older
who attend primary care clinics affiliated with Eskenazi
Health (EH) and Indiana University Health (IUH) serving
the cities of Indianapolis and Lafayette in Indiana. These
subjects will be randomly assigned at a ratio of 1:1 into “no
screening” or “screening” groups (2,000 patients per group;
Figure 1). Subjects randomized into the screening group
who have a positive screen will be further referred into an
existing primary care-based collaborative dementia care
program within the two health care systems. This col-
laborative dementia care program delivers evidence-based
diagnostic assessment, counseling, and management for pa-
tients with dementia and their informal caregivers [10,11].
All patient outcomes are measured at baseline, 1, 6, and
12 months, in person or via telephone. Health care
utilization and cost data for all subjects throughout the
12 month study period will be obtained from the Regional
Health Information Exchange in the study recruitment area
and the medical records of the local health care systems.
The study has been approved by the institutional review
boards of Indiana University and Purdue University in
Indianapolis, the University of Pittsburgh, and the local
board of Indiana University Health at Arnett Hospital (IRB#
1206009010). The CHOICE trial is registered with clinical-
trials.gov, Clinical Trials.gov Identifier NCT01699503.
Setting and study population
Subjects will be recruited through the Indiana University
Practice-Based Research Network (IU-PBRN) and local
electronic medical record (eMR) systems and will include
17 primary care centers affiliated with EH and IUH services
[4]. These two systems serve a diverse population of
insured and uninsured patients throughout the cities of
Indianapolis and Lafayette, IN, USA, and represent more
than 110 primary-care physicians, 100,000 patients,
and 300,000 visits annually. Data generated within the
IU-PBRN is collected and stored in the Indiana Network
for Patient Care (INPC), which serves as the central Indiana
Regional Health Information Exchange.
Recruitment and screening
We anticipate the need to identify 6,000 older adults to
enroll 4,000 subjects. Rolling enrollment will take place
4000 Pts consent  for and complete baseline data collection (HUI + PHQ-9 + GAD-7 + MOS) 
Randomized; ratio 1 to 1
2000 Pts into No screening  2000 Pts into Screening with MIS-T 
1700 Pts screen negative on MIS-T
300 Pts screen  positive on MIS-T
200 proceed to diagnosis program
100 Pts receive diagnosis of 
Normal or MCI
100 Pts receive diagnosis of Dementia and 
are managed by dementia care program 
100 Pts refuse evaluation
HUI: Health Utility Index; PHQ-9: Patient Health Questionnaire-9; GAD-7:  General Anxiety Disorder screener; MOS: Medical Outcome Study;  MIS-T: Memory Impairment 
Screen-telephone version; MCI: Mild Cognitive Impairment; HER-electronic health record.
Telephone -based re-evaluation at 1, 6, and 12 months (HUI + PHQ-9 + GAD-7 + MOS); EHR data acquisition
Figure 1 Study protocol flowchart.
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proximately 90 subjects. Among the participants in the
screening arm who screen positive, we anticipate that
the local collaborative dementia care program will man-
age an estimated 100 subjects with dementia (Figure 1).
The entire 4,000 subject cohort will be followed for
12 months.
The data managers of INPC or the local health care
systems will extract a list of eligible patients based on
the study’s inclusion criteria (e.g., patients cared for in
the targeted primary care practice, over the age of 65,
and without a diagnosis of dementia). The eligible list of
patients will be provided to the primary care clinicians
(PCPs) to authorize the study personnel to approach
their patients for potential participation. Once approved
by the PCPs, study personnel will approach eligible pa-
tients during their visit to their primary care clinic or via
the telephone to confirm eligibility and obtain informed
consent.
Eligibility
Our target population are primary care patients aged
65 years or older without a diagnosis of dementia orany cognitive impairment in their medical record.
Eligibility is established through a screening of the
INPC database or the local practice medical record,
and the assessments conducted by the research assis-
tants face-to-face or via the telephone.
Inclusion criteria
 Adults aged 65 and older
 At least one office visit to their EH or
IUH primary care physician within the
previous year
 No previous diagnosis of dementia or cognitive
impairment as determined by ICD-10 codes or
the presence of prescription for anti-dementia
medications (cholinesterase inhibitors or
memantine)
 Ability to consent to participate in the study
 Ability to communicate in English
Exclusion criteria
 Adults who are a permanent resident of a
nursing facility
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schizophrenia as determined by the presence of
related ICD-10 codes indicative of such an illness or
 A pre-existing diagnosis of dementia or cognitive
impairment
Following the confirmation of eligibility and obtaining
informed consent, all consenting subjects (screening and
non-screening arms) will complete the baseline assess-
ment which includes the HUI, the PHQ-9, the GAD-7,
the Medical Outcome Study (MOS), and seven questions
that inquire about the presence of an Advance Directive
and Power of Attorney for health care and financial affairs.
Following these assessments, if the participant has been
randomized to the screening arm, the research assistant
administers the Memory Impairment Screen (MIS-T).
The MIS-T takes approximately four minutes to complete
and has demonstrated excellent psychometric properties
in primary care and community samples with a positive
likelihood ratio of 33 [12,13]. The MIS-T has a total score
from 0 point to 8 points. A cut-score <5 has 86% sensiti-
vity and 91% specificity for dementia with a positive pre-
dictive value of 72% and negative predictive value of 96%
in a setting with a dementia prevalence of 15% [14,15].
Randomization and blinding
Randomization will occur at the patient level rather than
at the level of providers or clinics to minimize the effects
of unmeasured case mix differences and clinic-level clus-
tering. We estimate that the risk for “spillover” from ha-
ving participating clinics treat both intervention and usual
care patients is likely to be small given the current low
levels of detection of dementia in primary care [16,17]. If
anything, patient-based randomization will conservatively
bias the results in favor of usual care. Allocation of scree-
ning will be performed using a computer-generated sys-
tem. Patients will be assigned to screening using stratified
block randomization. Patients are randomized with a
block size of 4 and stratified by health care system (EH or
IUH).
At the beginning of the study, prior to enrollment, the
study biostatistician, using SAS software version 9.3 (SAS
Institute, Cary, NC, USA) generated a block randomi-
zation scheme to assign study identification numbers
either a screen or no screen status. The CHOICE study
coordinator, who is not blind to status, will prepare an
envelope for each study identification number that in-
cludes a piece of paper indicating whether that study iden-
tification number has been randomized to the screen or
no screen arm. The envelopes are sealed and then placed
in recruitment packets which are delivered to the research
assistants in sequential order. The research assistants open
the randomization envelope at the time of enrollment, fol-
lowing administration of the baseline assessment, andadminister the MIS-T if the participant has a number that
was randomized to the screening arm. The participants
and the study research coordinator who creates the
randomization envelopes for the recruitment packets are
not blinded to group assignment. However, the principal
investigators of the study, the research assistants respon-
sible for administering the outcome assessments, and the
lead biostatistician all remain blinded to individual assign-
ments. A second unblinded statistician is responsible for
assessing all screening data and assisting with analyses
that are reported to the Data Safety Monitoring Board
(DSMB) for its review of protocol implementation. The
DSMB, in turn, reports its findings to the project Principal
Investigator and Co-Investigators. This ensures that all
data about protocol deviations are available to the project
leaders without revealing the identification of participants.
Description of the intervention condition
Subjects who are randomized into the screening arm of
the trial and score less than 5 points on the MIS-T (e.g., a
positive screen) will be referred by the CHOICE study
coordinator to the local collaborative dementia care pro-
gram called the Aging Brain Center Medical Home (ABC
MedHome). Subjects who screen positive on the MIS-T
but are found to have no dementia by the subsequent
assessment will be referred for an annual cognitive assess-
ment with the local memory care practice at EH or IU
Health.
The goal of the ABC MedHome program is to assist pri-
mary care clinicians in achieving the recommended stan-
dard of care in the diagnosis and management of older
patients with dementia. Much of the intervention, facili-
tated by non-medical care coordinators, is targeted to co-
manage or support the practice behavior of primary care
clinicians, enhance self-management skills of both the
care-recipient and the informal caregiver, and maximize
the coping behavior of the patient and the informal care-
giver. By design, the previously-tested program protocols
lead to individualized and patient-centered profiles of
actual interventions for individual patients and their infor-
mal caregivers [18,19]. The program has four main phases:
the initial assessment phase, the plan of care development
phase, the second home visit phase, and the follow-up
phase.
In the initial assessment, the care coordinator conducts
a demographic and medical information interview, reviews
medication lists, and gathers and reviews any diagnostic
testing and brain imaging results with the primary in-
tention of identifying any potentially reversible causes of
dementia and co-morbid conditions. After completing a
pre-home-visit interview, the care coordinator travels to
and conducts a face-to-face initial assessment at the pa-
tient’s and/or informal caregiver’s residence or preferred
location. At the patient’s home, the care coordinator
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needs assessment of the patient and informal caregiver,
and medication reconciliation. The program uses stan-
dardized assessment tools including The Healthy Aging
Brain Care Monitor (HABC-M) [10,11]. If there is no
available or identified caregiver, the care coordinator
attempts to identify a caregiver and complete the caregiver
questions at a later date either by phone or in-person. The
care coordinator documents the initial and follow-up visits
using care coordination software called the eMR-ABC.
The second phase of the intervention is the develop-
ment of an individualized Care Plan with an emphasis
on coordinating care with the patient’s primary care pro-
vider. This phase begins after the first home visit and
concludes with a second home visit by the care coordi-
nator. After consultation and coordination with the ABC
MedHome medical director (a geriatrician or a neurolo-
gist) and the patient’s primary care physician, the ABC
MedHome care team (medical director and nurse) rules
in or out the diagnosis of dementia and its subtypes and
finalizes the individualized care plan with the primary
care physician. If necessary, the patient will be referred
for a more extensive cognitive and mental health eva-
luation at the local memory care practice.
Following the development of the care plan, the care co-
ordinator will schedule a second face-to-face home visit
with the patient and the informal caregiver within 2 to
4 weeks of the initial home visit. The key purpose of the
second home visit is for the care coordinator to disclose
the diagnosis, the natural history, and the prognosis of
dementia; implement appropriate care protocols; review,
explain, and distribute the corresponding educational
handouts for both the patient and the informal caregiver;
and connect patients and informal caregivers to in-home
services and community resources as needed.
The fourth and final phase of the ABC MedHome is the
follow-up and ongoing management of the patient. This
includes interaction with the patient or the caregiver via
face-to-face home or clinic visits, phone contact, or
contact by email, fax, or mail. The minimum amount of
contact during this time will be once monthly for the first
three months and once every three months there-
after. During these interactions, the care coordinator will
answer any questions generated from previous visits, col-
lect patient and informal caregiver feedback, reconcile
medications and review medication adherence, have the
informal caregiver complete the HABC-M to trigger the
use of specific care protocols, and facilitate the informal
caregiver’s participation in a local Support Group Program
sponsored by the local chapter of the Alzheimer’s Asso-
ciation. Throughout the duration of the follow-up phase,
the team will continue to work with the patient, the
informal caregiver, and the patient’s primary care pro-
vider to monitor, implement, and adjust as necessary theindividualized care plan. The program care, services, and
protocols during this phase are:
i) Self-management/caregiver skills enhancement
ii) Support group participation
iii) Informal telephone support
iv) Problem solving training
v) Reducing anticholinergic medications
vi) Prescribing FDA-approved medications
vii) Managing high vascular burden
viii)Monitoring and supporting of caregiver’s emotional
and physical health
ix) Managing transitional care
x) Managing acute care problems
xi) Root-cause analysis of re-hospitalization or
re-emergency room visits
xii) Care prioritization
xiii)Discharge criteria
Description of control condition
The 2,000 subjects who are randomized into the no
screening group will serve as a usual care control group
and continue to receive their usual primary care, inclu-
ding a referral to the local memory care practices if their
primary care provider suspects the presence of a cogni-
tive problem at any time during the study.
Primary and secondary outcome measures
The primary outcome measure will be patient health-
related quality of life (HRQOL) measured at 1, 6, and
12 months among the entire 4,000 enrollees. We will use
the 15-item HUI to determine the subject’s HRQOL and
change in HRQOL [20]. The HUI is a generic, utility-
based HRQOL instrument applied in patients with a wide
range of medical conditions including dementia [21,22]. It
has eight attributes: vision, hearing, speech, ambulation,
dexterity, emotion, cognition, and pain. The individual
health domain scores range from 0.00 (maximum impair-
ment) to 1.00 (no impairment) and the multi-attribute
(HUI index) scores, a multiplicative function of individual
attribute levels, range from 0.36 to 1.00 with anchors
0.00 = dead and 1.00 = perfect health. Naglie et al. found
that test-retest reliability exceeded the standard for
adequate reliability of 0.70 in those with mild dementia
(ICC = 0.75) [22]. Vickrey et al. [23] found that the mean
HUI multi-attribute utility score for 408 primary care pa-
tients with dementia was 0.54 (SD = 0.23) and the mean
one year change was −0.30 among 240 dementia patients
who remained in their own home after one year of recei-
ving the dementia care program whereas the mean one
year change was −0.76 among 29 dementia patients who
moved into a skilled nursing home facility.
The second primary outcomes for the CHOICE trial are
patient mood and anxiety as measured by the PHQ-9
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sion scale with a total score from 0 to 27, and the GAD-7
is a 7-item anxiety scale with a total score from 0 to 21.
Both of these scales are derived from the Patient Health
Questionnaire and have good internal consistency and
test-retest reliability as well as convergent, construct, cri-
terion, procedural, and factorial validity for the diagnosis of
major depression and general anxiety disorders [24-27]. In
our previous primary care studies of community-dwelling
older adults, the mean PHQ-9 scores ranged from 3.8
(SD = 5.1) to 4.4 (SD = 5.6) and the mean GAD scores
ranged from 2.7 (SD = 3.2) to 3.2 (SD = 3.5) [4,10,11]. The
research assistants will notify the study coordinator if any
subjects express thoughts or demonstrate tendencies of
self-harm with a positive response on the PHQ-9 question
about suicidal thoughts. The CHOICE study coordinator
will keep a detailed log of these events and will notify the
subject’s primary care provider immediately.
To conduct a cost effective analysis of CHOICE, we will
use both the INPC database and the local eMR to identify
all episodes of ambulatory or acute care utilization occur-
ring within the 12 months before and after enrollment.
We will structure continuous variables that describe the
number of ambulatory and/or acute care episodes.
Additional outcomes of the trial include measures of so-
cial support, advance care planning information (e.g., hav-
ing power of attorney for health care and/or financial
affairs, having a living will, and having life and additional
insurance policies), and evidence of any dementia recogni-
tion by providers using the same ICD codes used to iden-
tify eligible subjects. Additional data that will be collected
includes patient age, gender, race, education, income,
living situation, marital status, medications, and presence
of any of 10 chronic conditions as indicated by ICD-10
codes in the medical record (arthritis, congestive heart
failure, coronary artery disease, cancer, chronic obstructive
pulmonary disease, diabetes, stroke, hypertension, kidney
disease, and liver disease). Given the pragmatic design of
CHOICE and that participants in the control group may
receive dementia screening and dementia care processes
as part of their routine primary care, the study will use the
local eMR and the eMR-ABC MedHome to measure de-
mentia care processes for both the control and the inter-
vention groups. This includes all patient contacts by the
local memory care or primary care practices, referrals to
local Alzheimer’s disease support groups, the use of home
health services, and assessment of the level of participa-
tion of patients and caregivers in the ABC MedHome pro-
gram. An overview of the data is presented in Table 1.
Analysis plan
Study arm comparison
To verify the comparability of the randomized groups,
baseline characteristics of the screened and no screeningpatient groups will be compared using t-tests for con-
tinuous variables and χ2 tests for categorical variables.
We will carefully examine the distributions of continu-
ous variables and use alternative approaches such as
transformation or non-parametric methods in cases of
violation to the normal distribution assumption. We also
will examine the frequency distribution of all categorical
variables and adopt exact inference procedures in cases
of zero or small cell size. We will compare the baseline
characteristics of subjects with missing outcomes due to
death or refusal at 12 months to subjects who complete
the follow-up to detect potential violation to the missing
at random assumption. Further sensitivity analyses will
be performed using various methods of imputation or a
full parametric likelihood approach assuming various
patterns of missing data [28].
Analyses for the primary aim will compare mean mea-
sures of HRQOL from the HUI in the screening group to
the no screening group using analysis of covariance
(ANCOVA) while including baseline measures as cova-
riates. We will first conduct the ANCOVA models sepa-
rately for outcomes obtained at 12 months while adjusting
for baseline measures. We will then use the mixed effect
models to examine whether the difference between the
two groups changes over time using repeated HUI mea-
sures as the dependent variables and group, time, and
interaction between groups as independent variables while
controlling for other baseline covariates. Patients who do
not complete the 12-month surveys for HRQOL will be
excluded from the analyses followed by sensitivity analyses
on missing data.
Analyses for the secondary outcome measures will
compare change in depression and anxiety levels post
dementia screening between screened subjects and sub-
jects in the no screening group. ANCOVA models will
be used to compare change in PHQ-9 and GAD-7 scores
from baseline to 1 month between the screening and no
screening groups adjusting for patients’ characteristics
and baseline measures. Mixed effect models similar to
those used for HUI will be used to determine whether
depression and anxiety changes over time are different
for the two groups.
For the cost-effectiveness aim, we will estimate the
cost of the dementia screening program in comparison
to no screening. The estimations will include the cost of
the collaborative dementia care program for those who
screen positive. This economic evaluation will be con-
ducted from both the societal and payer (Medicare) per-
spectives. The societal perspective will capture caregiver
and patient time and transportation costs and the effect
on quality of life for patients and caregivers [29]. Medi-
care payments for health care utilization will be valued.
Costs will be divided into fixed and variable costs and by
the screening, initial assessment phase, and follow-up
Table 1 Overview of data sources
Construct Source of data Specific variables/instruments
Social, demographic, advance care planning Study survey MOS, age, gender, race, education, income, living
situation, marital status, and advance care planning
Health related quality of life, mood
and anxiety
Study survey HUI, PHQ-9, GAD-7
Health care utilization Indiana Network for Patient Care records or the
local eMR at IUH Arnett for the 4,000 subjects
ER episode, location
Hospital episode, location
Inpatient diagnoses (ICD-10 codes)
Length of stay
Co-morbidity Indiana Network for Patient Care records or the
local eMR at IUH Arnett for the 4,000 subjects
ICD-10 codes for the 10 common chronic diseases
Medication use Indiana Network for Patient Care records or the
local eMR at IUH Arnett for the 4,000 subjects
Psychotropics
Care Processes eMR-ABC and INPC Visits to memory care practice.
Collaborative dementia care team visit.
Visits with HABC-M
Protocols delivered by the care team
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will be estimated for the control and screening groups
from health care utilization and reimbursement data
captured by both INPC database and the local medical
records of EH and IUH during the trial. The cost ana-
lysis will control for non-dementia related conditions
such as stroke, cancer, and diabetes that are known to
be associated with increased health care utilization and
costs. Program or activity costing will be conducted to
estimate the costs necessary to implement and operate
the screening and collaborative dementia care manage-
ment program and the usual care for dementia patients.
The program costs can be compared to the risk adjusted
economic savings estimate comparing the intervention
to usual care for the calculation of net present value and
cost benefit ratios. Patient and caregiver time, staff time,
fringe benefits, overhead costs, and materials will be
logged by staff using the care coordination software used
by the ABC MedHome and assessed for the 12-month
follow-up period. Transportation costs will be estimated
from data on distance from home to clinic. Health care
contacts will be dated and checked to avoid double
counting via claims and activity costing methods. Pre-
scription drugs will be valued at the median wholesale
price, and a dispensing fee will be added for each 100
doses. Unit wage costs and fringe benefits will be stan-
dardized applying median values paid to personnel in
the region, with wage data collected from the health care
system partners. Costs will be accumulated during the
trial based on the probability of survival each month
times the monthly cost of care for survivors to address
censoring [30]. Effects and costs will be discounted at a
3% annual rate for the trial period. The ICER, willcompare the no screening and less resource intensive
usual care treatment strategy (UC) with the screening
coupled with the more intensive treatment intervention
(the collaborative dementia care program) using the fol-
lowing formulas for (1) dementia patients (AP) and (2)
Dementia patients plus their caregivers (CG).
ICERAP ¼ COSTHABC−COSTUC½ 
 QALYHABC−QALYUC½  ð1Þ
ICERAPþCG ¼ COSTHABC−COSTUC½ 
 QALYHABC−QALYUC½  ð2Þ
Uncertainty in the cost-effectiveness ratios and 95%
confidence intervals will be assessed with 1,000 bootstrap
samples. The outcome of each sample will be expressed as
a scatter plot of incremental costs and effects generated
from the bootstrap samples, reflecting the uncertainty
arising from the model parameters. Results will also be
displayed using net benefit analysis and cost-effectiveness
acceptability curves (CEAC) [31]. There is controversy
about the appropriate ceiling ratio for health benefits [32].
Garber et al. have recommended that a value of twice the
median annual per capita income will result in efficient re-
source allocation [32].
The effects on ICERs of alternative unit cost estimates
for caregiver time value and overhead cost rate for the
screening and coordinated care management will be exa-
mined in a series of one-way and multi-way sensitivity
analyses. The ceiling ratio λ will be varied from $30,000
to $100,000 per QALY for the CEAC analysis. The cost-
effectiveness hypothesis will be tested against the $60,000
per QALY maximum willingness to pay norm [33].
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Assuming 85% sensitivity of the MIS-T screening instru-
ment and 15% prevalence of dementia in this patient
population, to achieve 80% power to detect a signifi-
cance effect size of 0.094 between the screening group
and the no screening group at α = 0.05 level (two-sided),
and allowing 10% of patients with missing follow-up
outcomes at 12 months, we need to enroll at least 3,951
patients into the study. The effect size of 0.094 for the
screening group and the no screening group reflects
a difference of 0.40 standard deviation (SD) between
demented patients in the collaborative dementia care
program and demented patients who were not screened
and a difference of 0.06 SD in the majority of patients
who are not demented in either group. We demonstrate,
in Table 2, that our planned sample size of 4,000 will
have sufficient power to detect significant differences
between the screen group and the no screen group
under various scenarios assuming varying degrees of ef-
ficacy measures for the collaborative dementia care pro-
gram and for the screening only subjects.
For the second primary aims of change in patient mood
and anxiety, given the sample size of 4,000, we will have
greater than 95% power to test the equivalence levels in
PHQ-9 and GAD-7 at 1 month assuming equivalence dif-
ferences of 0.6 (SD = 5.1) on PHQ-9 and 0.5 (SD = 3.2) on
GAD-7 based on our previous studies of primary care pa-
tients [34-38].
Discussion
Despite the availability of pharmaceutical and life-style
interventions that show some benefit in the treatment of
dementia [7,8,39-41], there is no cure. Results from the
literature indicate that most older adults would accept
screening for dementia [37,42], yet few primary care
physicians conduct dementia screening, and as many as
50% of PCPs are unaware of their older patients’ cogni-
tive status [43,44]. While the United States Preventive
Services Task Force has determined that the need for
screening non-symptomatic patients for dementia in pri-
mary care is unsubstantiated, the Center for MedicareTable 2 Estimated power with a total sample size of
4,000 comparing primary outcome measures between
the screening group and the no screening group
(two-sided at α = 0.05) allowing 10% of patients with
missing outcomes at 12 months
Effect size of
collaborative care in
demented subjects
Effect size in
non-demented
subjects
Observable
effect size
Power
estimate
0.3 0.07 0.091 77.9
0.08 0.100 85.1
0.4 0.07 0.102 86.4
0.08 0.110 91.0and Medicaid Services and expert recommendations on
the comprehensive care of older adults encourage early
detection of dementia [6,9,4].
The CHOICE Trial is the first study to assess the harms,
benefits, and cost effectiveness of screening for dementia.
CHOICE will compare patient outcomes of screening
when linked to a state-of-the-art treatment program and
no screening among 4,000 older adults cared for in typical
urban and suburban primary care practices. In this prag-
matic trial, patients in the no screening control arm may
be screened as part of routine primary care. Patients in
the screening arm who screen positive will be referred to
an evidence-based best practice model, the ABC Med-
Home, for assessment and long-term management of the
patient and caregiver.
The CHOICE trial has some limitations. The major
limitation is its short 12-month follow-up duration.
Dementia is a chronic condition that worsens over time;
while one year of observation will provide time to monitor
changes in the outcomes selected for this trial, it does not
provide a long enough observation window for more distal
outcomes such as nursing home placement or mortality.
From prior studies, we know that one year of follow-up
data is sufficient to detect the impact of the collaborative
dementia care program on screened detected patients with
dementia. In our clinical trial of the collaborative demen-
tia care program, we were able to identify a clinically rele-
vant effect within 12 months [10,11,18,19].
Perhaps the largest threat to the study as proposed, is
meeting the enrollment target. The research infrastruc-
tures available for our study and the extensive expe-
rience of our investigators in enrolling similar large and
vulnerable populations greatly increase our likelihood of
success in recruiting 4,000 subjects within 45 months. In
addition, we have contingency plans to double our num-
ber of potentially eligible subjects by using additional
IU-affiliated primary care clinics with access to more
than 30,000 older adults aged 65 and older.
Trial status
Ongoing and as of December 31, 2013, the trial has re-
cruited more than 750 subjects.
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